RS68134B1 - Lečenje prezbiopije i midrijaze fentolaminom - Google Patents

Lečenje prezbiopije i midrijaze fentolaminom

Info

Publication number
RS68134B1
RS68134B1 RS20260626A RSP20260626A RS68134B1 RS 68134 B1 RS68134 B1 RS 68134B1 RS 20260626 A RS20260626 A RS 20260626A RS P20260626 A RSP20260626 A RS P20260626A RS 68134 B1 RS68134 B1 RS 68134B1
Authority
RS
Serbia
Prior art keywords
patient
eye
phentolamine mesylate
dose
pupil diameter
Prior art date
Application number
RS20260626A
Other languages
English (en)
Serbian (sr)
Inventor
William H Pitlick
Alan R Meyer
Mina Sooch
Konstantinos Charizanis
Bernhard Hoffmann
Original Assignee
Opus Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70330746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS68134(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opus Genetics Inc filed Critical Opus Genetics Inc
Publication of RS68134B1 publication Critical patent/RS68134B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
RS20260626A 2018-10-26 2019-10-25 Lečenje prezbiopije i midrijaze fentolaminom RS68134B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751391P 2018-10-26 2018-10-26
PCT/US2019/058182 WO2020087021A1 (en) 2018-10-26 2019-10-25 Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
EP19875716.3A EP3870170B1 (en) 2018-10-26 2019-10-25 Treatment of presbyopia and mydriasis with phentolamine

Publications (1)

Publication Number Publication Date
RS68134B1 true RS68134B1 (sr) 2026-06-30

Family

ID=70330746

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260626A RS68134B1 (sr) 2018-10-26 2019-10-25 Lečenje prezbiopije i midrijaze fentolaminom

Country Status (24)

Country Link
US (8) US10993932B2 (enExample)
EP (2) EP4721725A3 (enExample)
JP (2) JP7670945B2 (enExample)
KR (2) KR102961961B1 (enExample)
CN (1) CN113164452A (enExample)
AU (2) AU2019366451C1 (enExample)
BR (1) BR112021007725A2 (enExample)
CA (1) CA3116589A1 (enExample)
DK (1) DK3870170T3 (enExample)
ES (1) ES3072078T3 (enExample)
FI (1) FI3870170T3 (enExample)
HR (1) HRP20260652T1 (enExample)
IL (1) IL282624A (enExample)
LT (1) LT3870170T (enExample)
MX (1) MX2021004708A (enExample)
PH (1) PH12021550882A1 (enExample)
PL (1) PL3870170T3 (enExample)
PT (1) PT3870170T (enExample)
RS (1) RS68134B1 (enExample)
SG (1) SG11202104094YA (enExample)
SI (1) SI3870170T1 (enExample)
SM (1) SMT202600236T1 (enExample)
WO (1) WO2020087021A1 (enExample)
ZA (1) ZA202102488B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899342C (en) * 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US12653779B2 (en) 2015-06-18 2026-06-16 Lenz Therapeutics Operations, Inc. Compositions and methods for the treatment of presbyopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
EP4153166A1 (en) * 2020-05-18 2023-03-29 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
JP2024515714A (ja) * 2021-04-23 2024-04-10 オキュフィア・ファーマ・インコーポレイテッド 散瞳、緑内障、及び他の眼の病態を治療するための方法及び組成物
JP6917103B1 (ja) * 2021-05-17 2021-08-11 株式会社坪田ラボ 近視抑制用点眼剤
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
TW202339703A (zh) * 2021-12-23 2023-10-16 瑞士商愛爾康公司 用於藥物遞送的可溶解醫療裝置
US20250127760A1 (en) * 2021-12-28 2025-04-24 Shenyang Xingqi Pharmaceutical Co., Ltd. Composition and use thereof in preparation of medicament for treating presbyopia
US20230263727A1 (en) * 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US11969410B2 (en) 2022-02-09 2024-04-30 Somerset Therapeutics, Llc Low pH pilocarpine and brimonidine compound formulations and related methods
AU2023257375A1 (en) * 2022-04-21 2024-11-07 Glaukos Corporation Ophthalmic topical cream compositions
CN114796496B (zh) * 2022-05-09 2023-06-23 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 交感神经活化抑制剂和/或α1-肾上腺素能受体抑制剂在制备治疗干眼症的药物中的应用
CN119768185A (zh) * 2022-08-31 2025-04-04 坪田实验室股份有限公司 包含α1阻断剂的抑制近视进展用滴眼剂
WO2024220441A1 (en) * 2023-04-17 2024-10-24 Lenz Therapeutics Operations, Inc. Methods for the treatment of presbyopia
EP4559900A1 (en) * 2023-11-21 2025-05-28 Opus Genetics, Inc. Phentolamine mesylate and therapeutic uses thereof
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia
WO2025230326A1 (ko) * 2024-04-30 2025-11-06 주식회사태준제약 필로카르핀을 포함하는 점안 조성물

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4443441A (en) 1981-08-07 1984-04-17 Galin Miles A Fixation of intraocular lenses
US4629456A (en) 1981-09-18 1986-12-16 Edwards David L Target ring for an eye dropper bottle
US4515295A (en) 1983-09-06 1985-05-07 St. Luke's Hospital Eye dropper with light source
US4590202A (en) 1984-01-19 1986-05-20 Merck & Co., Inc. N-(2-imidazolidinylidene)-5H-dibenzo[a,d]cyclohepten-5-amine compounds and α2 -adrenergic antagonistic uses thereof
US4659714A (en) 1984-03-27 1987-04-21 Dentsply, Ltd. Anesthetic methods for mammals
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
IE60588B1 (en) 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US4834727A (en) 1987-12-08 1989-05-30 Cope Samuel M Eye dropper bottle attachment for post-surgical and general use
US5261903A (en) 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
US5149320A (en) 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5059188A (en) 1990-03-28 1991-10-22 Goddard Larry C Eye dropper attachment
US5192527A (en) 1991-07-01 1993-03-09 Abrahmsohn Glenn M Method of reversing local anesthesia and reagent system therefor
JPH07508751A (ja) 1992-07-02 1995-09-28 テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド 老視治療のための方法および生産品
US5288759A (en) 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US5514118A (en) 1992-12-23 1996-05-07 Kummer; Frederick J. Measured dose eye dropper
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
AU3609795A (en) 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5584823A (en) 1995-07-20 1996-12-17 Ontario Incorporated Illuminated eye dropper device
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5627611A (en) 1995-12-29 1997-05-06 Scheiner; Stanley A. Artificial tears
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6432401B2 (en) 2000-05-12 2002-08-13 Novalar Pharmaceuticals, Inc. Local anesthetic methods and kits
CA2279651A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
KR100195348B1 (ko) 1996-10-31 1999-06-15 장용택 안정한 프로스타글란딘 e1-함유 주사제 조성물
US5891882A (en) 1996-12-06 1999-04-06 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine α-1 adenergic compounds
AU8667898A (en) 1997-08-05 1999-03-01 Mount Sinai School Of Medicine Of The City University Of New York, The Use of alpha1a-adrenergic receptor antagonists in glaucoma therapy
US6001845A (en) 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US5885550A (en) 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US20020082288A1 (en) 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US6420407B1 (en) * 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US20060211753A1 (en) 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6515006B2 (en) * 2000-11-08 2003-02-04 Hmt Pharma, Inc. Ophthalmic formulation which modulates dilation
US6982079B2 (en) 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
BRPI0311965B1 (pt) 2002-06-20 2018-04-24 Septodont Holding Sas Formulação líquida estável e seu uso para aumentar fluxo sanguíneo em mamífero, método de preparação de forma de dosagem única de formulação líquida estável, bem como recipiente e kit
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
WO2006041875A1 (en) 2004-10-06 2006-04-20 Allergan, Inc. Novel prostamides for the treatment of glaucoma and related diseases
US7868035B2 (en) 2005-02-01 2011-01-11 Allergan, Inc. Therapeutic esters
US20060257388A1 (en) 2005-05-13 2006-11-16 Julius Knowles Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2007008666A2 (en) 2005-07-08 2007-01-18 Ocularis Pharma, Inc. Compositions and methods for improving vision using adherent thin films
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
WO2008009141A1 (en) 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists
ATE439863T1 (de) 2006-12-18 2009-09-15 Jorge Luis Benozzi Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie
GB0700380D0 (en) 2007-01-09 2007-02-14 Breath Ltd Storage Of Ampoules
CA2621616A1 (en) 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20090131303A1 (en) 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20090220618A1 (en) 2008-02-29 2009-09-03 Erning Xia Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
AU2009225931B9 (en) 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
US20100028266A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
CN101463009B (zh) 2009-01-14 2010-09-22 天津市中央药业有限公司 一种甲磺酸酚妥拉明的合成方法
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US20130143938A1 (en) 2009-07-27 2013-06-06 Eye Therapies Llc Compositions and Methods for the Treatment of Migraine
US20110178147A1 (en) 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
WO2011050030A1 (en) 2009-10-21 2011-04-28 Allergan, Inc. Alpha adrenergic receptor modulators
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011237646A1 (en) 2010-04-09 2012-11-08 Allergan, Inc. Ketorolac compositions for corneal wound healing
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130172357A1 (en) 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
JP2014506936A (ja) 2011-03-03 2014-03-20 アラーガン インコーポレイテッド シリコーンベースの眼科製剤
WO2012149381A1 (en) 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2776603B1 (en) 2011-11-11 2019-03-06 SiO2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
WO2013078554A1 (en) 2011-12-02 2013-06-06 University Health Network Compositions of tigecycline and uses thereof
WO2013115844A1 (en) 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
WO2013130577A2 (en) 2012-02-27 2013-09-06 Eye Therapies, Llc Compositions and methods for the treatment of migraine
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CA2899342C (en) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
US8597629B1 (en) 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
CH711969A2 (it) 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
KR102472774B1 (ko) 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도
EP3654964B1 (en) 2017-07-20 2024-04-24 Seinda Pharmaceutical Guangzhou Corporation Composition comprising atropine and a miotic agent and its use in the treatment of myopia
EP3749303A4 (en) 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF AN ANTIMUSCARINE OR ANTICCHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼の状態の治療のためのピロカルピン塩酸塩の使用
CA3108992A1 (en) 2018-08-08 2020-02-13 Seinda Pharmaceutical Guangzhou Corporation Compositions and methods for treatment of presbyopia
US20210369686A1 (en) 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
EP3965732A4 (en) 2019-05-08 2023-06-14 Harrow IP, LLC PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA AND PROCESS FOR THEIR PREPARATION
WO2020252061A1 (en) 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects
EP3980017A4 (en) 2019-06-10 2023-06-28 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
US20240139166A1 (en) 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
JP2024515714A (ja) 2021-04-23 2024-04-10 オキュフィア・ファーマ・インコーポレイテッド 散瞳、緑内障、及び他の眼の病態を治療するための方法及び組成物
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
TW202333700A (zh) 2021-12-16 2023-09-01 美商倫茨治療公司 用於治療眼病之組成物及方法

Also Published As

Publication number Publication date
SMT202600236T1 (it) 2026-07-16
JP7670945B2 (ja) 2025-05-01
US20230040217A1 (en) 2023-02-09
WO2020087021A1 (en) 2020-04-30
US12201616B2 (en) 2025-01-21
EP3870170A4 (en) 2022-07-20
US12576067B2 (en) 2026-03-17
KR20260074407A (ko) 2026-05-22
AU2019366451B8 (en) 2025-08-07
MX2021004708A (es) 2021-11-03
US20220226287A1 (en) 2022-07-21
CA3116589A1 (en) 2020-04-30
US12576066B2 (en) 2026-03-17
JP2022505950A (ja) 2022-01-14
BR112021007725A2 (pt) 2021-07-27
KR20210096096A (ko) 2021-08-04
EP4721725A2 (en) 2026-04-08
IL282624A (en) 2021-06-30
US20230032637A1 (en) 2023-02-02
US12016841B2 (en) 2024-06-25
PL3870170T3 (pl) 2026-06-29
PT3870170T (pt) 2026-06-25
US20210346349A1 (en) 2021-11-11
KR102961961B1 (ko) 2026-05-11
US20200253931A1 (en) 2020-08-13
AU2019366451B1 (en) 2025-07-17
DK3870170T3 (da) 2026-05-26
HRP20260652T1 (hr) 2026-07-17
EP4721725A3 (en) 2026-06-03
US11400077B2 (en) 2022-08-02
ZA202102488B (en) 2022-10-26
AU2019366451A1 (en) 2021-05-20
JP2025032074A (ja) 2025-03-11
US10993932B2 (en) 2021-05-04
AU2019366451C1 (en) 2026-01-15
SG11202104094YA (en) 2021-05-28
ES3072078T3 (en) 2026-06-29
US20250161274A1 (en) 2025-05-22
US12201615B2 (en) 2025-01-21
US20250161275A1 (en) 2025-05-22
EP3870170B1 (en) 2026-02-25
LT3870170T (lt) 2026-06-10
PH12021550882A1 (en) 2022-02-21
FI3870170T3 (fi) 2026-05-21
US20200246310A1 (en) 2020-08-06
AU2024219970A1 (en) 2024-10-10
EP3870170A1 (en) 2021-09-01
CN113164452A (zh) 2021-07-23
SI3870170T1 (sl) 2026-07-31